Olanzapine

Summary

Olanzapine (CHEMBL715) is an approved small-molecule histamine antagonist (ATC N05AH03) targeting HTR6, HTR7, and HTR1A; indicated across 39 conditions including psychotic disorder and schizoaffective disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AH03
• Targets: 13 (HTR6, HTR7, HTR1A…)
• Indications: 39 conditions
• Clinical trials: 357
• Chemistry: 312.4 Da · C17H20N4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL715
Name	Olanzapine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	135398745
ChEBI	CHEBI:7735
ATC	N05AH03
Molecular formula	C17H20N4S
Molecular weight	312.4
InChIKey	KVWDHTXUZHCGIO-UHFFFAOYSA-N

SMILES: CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C

IUPAC name: 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine

ChEBI definition: A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.

Pharmacological roles (ChEBI): histamine antagonist, muscarinic antagonist, serotonergic antagonist, dopaminergic antagonist, antiemetic, second generation antipsychotic, serotonin uptake inhibitor.

Also known as: Arkolamyl, LY-170053, LY170053, Olansek, Olanzapina, Olanzapine, Olanzapine apotex, Olanzapine cipla, Olanzapine component of lybalvi, Olanzapine component of symbyax, Olanzapine glenmark, Olanzapine glenmark europe

Parent form; salt/anhydrous children: CHEMBL3989694

Patent coverage: 10,451 distinct patent families (40,057 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 39,734 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR6	5-HT6 receptor	Inverse agonist	8	0.2%	P50406
HTR7	5-HT7 receptor	Antagonist	6.5	0.8%	P34969
HTR1A	5-HT1A receptor	Full agonist	5.8	0%	P08908
DRD2	D2 receptor	Antagonist	8.68	0%	P14416
ADRA1A	α1A-adrenoceptor	Antagonist	7.4		P35348
ADRA1D	α1D-adrenoceptor	Antagonist	6.4	0.2%	P25100
HRH1	H1 receptor	Antagonist	9.2	0%	P35367
HTR1B	5-HT1B receptor	Full agonist	6.3	0.2%	P28222
HTR1D	5-HT1D receptor	Full agonist	6.2	0%	P28221
HTR1E	5-ht1e receptor	Full agonist	5.7	0%	P28566
HTR1F	5-HT1F receptor	Full agonist	6.5	0.1%	P30939
HTR2A	5-HT2A receptor	Antagonist	8.9	0%	P28223
HTR2C	5-HT2C receptor	Inverse agonist	8.4	0%	P28335

Broader ChEMBL bioactivity targets: 66 (assay-derived). Sample: Ubiquitin carboxyl-terminal hydrolase 2, Prelamin-A/C, Inositol monophosphatase 1, FAD-linked sulfhydryl oxidase ALR, Muscarinic acetylcholine receptor M4, 5-hydroxytryptamine receptor 2B, D(1B) dopamine receptor, Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 3A.

Bioactivity

ChEMBL activities: 328 potent at pChembl ≥ 5 of 338 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	10.06	Kd	0.09	nM	CHEMBL_ACT_12049048
P31390	9.52	Ki	0.3	nM	CHEMBL_ACT_410822
HTR2A	9.38	Ki	0.42	nM	CHEMBL_ACT_22411681
HRH1	8.92	Ki	1.2	nM	CHEMBL_ACT_1518330
HTR2A	8.84	Ki	1.43	nM	CHEMBL_ACT_7737995
HRH1	8.83	Ki	1.47	nM	CHEMBL_ACT_7735891
HTR2A	8.8	Ki	1.58	nM	CHEMBL_ACT_1925235
HTR2A	8.72	Ki	1.91	nM	CHEMBL_ACT_24412729
HTR2A	8.72	Ki	1.9	nM	CHEMBL_ACT_436258
HTR2A	8.72	Ki	1.9	nM	CHEMBL_ACT_688681
HRH1	8.7	Ki	2	nM	CHEMBL_ACT_14583577
HRH1	8.7	Ki	2	nM	CHEMBL_ACT_16282089
DRD2	8.68	Ki	2.1	nM	CHEMBL_ACT_688677
CHRM1	8.68	Ki	2.1	nM	CHEMBL_ACT_688685
HTR2A	8.64	Ki	2.3	nM	CHEMBL_ACT_1518326
HTR2A	8.6	Ki	2.5	nM	CHEMBL_ACT_14580734
HTR2A	8.6	Ki	2.5	nM	CHEMBL_ACT_16333810
HTR2A	8.6	AC50	2.5	nM	CHEMBL_ACT_25173651
HTR2A	8.6	Ki	2.5	nM	CHEMBL_ACT_26580321
HRH1	8.55	Ki	2.8	nM	CHEMBL_ACT_2556770
HTR2C	8.55	Ki	2.8	nM	CHEMBL_ACT_688682
HTR2A	8.48	Ki	3.3	nM	CHEMBL_ACT_15060303
HTR2A	8.48	Ki	3.3	nM	CHEMBL_ACT_2577189
HRH1	8.46	Ki	3.5	nM	CHEMBL_ACT_436263
HTR2A	8.4	Ki	4	nM	CHEMBL_ACT_1197309
HTR2A	8.4	Ki	4	nM	CHEMBL_ACT_12720301
P14842	8.4	Ki	4	nM	CHEMBL_ACT_1420005
HTR2A	8.4	Ki	4	nM	CHEMBL_ACT_15083426
DRD2	8.4	Ki	4	nM	CHEMBL_ACT_18653021
HTR2A	8.4	Ki	4	nM	CHEMBL_ACT_18653174

Target pathways

Aggregated over 13 target gene(s): HTR6, HTR7, HTR1A, DRD2, ADRA1A, ADRA1D, HRH1, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C.

Top Reactome pathways

15 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	11	ADRA1A, ADRA1D, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
Signaling by GPCR	11	ADRA1A, ADRA1D, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
Class A/1 (Rhodopsin-like receptors)	11	ADRA1A, ADRA1D, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
Amine ligand-binding receptors	11	ADRA1A, ADRA1D, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
GPCR ligand binding	11	ADRA1A, ADRA1D, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
GPCR downstream signalling	10	ADRA1A, ADRA1D, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
Serotonin receptors	9	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
G alpha (q) signalling events	5	ADRA1A, ADRA1D, HRH1, HTR2A, HTR2C
G alpha (i) signalling events	4	HTR1B, HTR1D, HTR1E, HTR1F
Adrenoceptors	2	ADRA1A, ADRA1D
G alpha (12/13) signalling events	2	ADRA1A, ADRA1D
G alpha (s) signalling events	2	HTR6, HTR7
Histamine receptors	1	HRH1
Dopamine receptors	1	DRD2
RHOBTB3 ATPase cycle	1	HTR7

Dominant GO biological processes

GO term	Targets
signal transduction	13
G protein-coupled receptor signaling pathway	13
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	10
chemical synaptic transmission	10
G protein-coupled serotonin receptor signaling pathway	5
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5
phospholipase C-activating G protein-coupled receptor signaling pathway	5
adenylate cyclase-activating G protein-coupled receptor signaling pathway	4
positive regulation of ERK1 and ERK2 cascade	4
positive regulation of vasoconstriction	4
phospholipase C-activating serotonin receptor signaling pathway	4
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	4
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	3
smooth muscle contraction	3
vasoconstriction	3

Indications & clinical

Indications

39 indications (9 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407
schizoaffective disorder	4	MONDO:0005487	EFO:0005411
major depressive disorder	4	MONDO:0002009	EFO:0003761
bipolar disorder	4	MONDO:0004985	EFO:0009963
mental disorder	4	MONDO:0005084	EFO:0000677
eating disorder	3	MONDO:0005451	EFO:0005203
pathological gambling	3	MONDO:0011662	EFO:0004699
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
borderline personality disorder	3	MONDO:0001156	HP:0012076
developmental disability	3	MONDO:0005287	EFO:0003852
neoplasm	3	MONDO:0005070	EFO:0000616
depressive disorder	3	MONDO:0002050	MONDO:0002050
testicular cancer	3	MONDO:0005447	EFO:0005088
alcohol abuse	3	MONDO:0002046	MONDO:0007079
Huntington disease	3	MONDO:0007739	MONDO:0007739
intellectual disability	3	MONDO:0001071	HP:0001249
female reproductive organ cancer	3	MONDO:0001416	EFO:1001331
autism	2	MONDO:0005260	EFO:0003758
delirium	2	MONDO:0045057	EFO:0009267
opiate dependence	2	MONDO:0005530	EFO:0010702
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
anorexia nervosa	2	MONDO:0005351	MONDO:0005351
mood disorder	1	MONDO:0005371	EFO:0004247
drug-induced dyskinesia	1	MONDO:0006732	EFO:1000904

14 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 357.

Phase distribution

Phase	Trials
PHASE4	110
PHASE3	101
Not specified	55
PHASE2	46
PHASE1	28
PHASE2/PHASE3	8
PHASE1/PHASE2	7
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04478838	PHASE4	RECRUITING	Extended (Alternate Day) Antipsychotic Dosing
NCT06133114	PHASE4	RECRUITING	Psychopharmacological Treatment of Emotional Distress
NCT07047651	PHASE4	ACTIVE_NOT_RECRUITING	Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.
NCT07482891	PHASE4	RECRUITING	An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
NCT00000373	PHASE4	COMPLETED	Treatment of Obsessive-Compulsive Disorder
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034580	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048802	PHASE4	COMPLETED	Treatment and Outcome of Early Onset Bipolar Disorder
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00050206	PHASE4	COMPLETED	Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder
NCT00071253	PHASE4	TERMINATED	Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00094549	PHASE4	COMPLETED	Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00177567	PHASE4	COMPLETED	Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
NCT00181935	PHASE4	COMPLETED	Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder
NCT00182013	PHASE4	COMPLETED	Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder
NCT00182442	PHASE4	COMPLETED	Cognition, Functioning and Quality of Life
NCT00182507	PHASE4	COMPLETED	Olanzapine in the Treatment of Hair Pulling (Trichotillomania)
NCT00183625	PHASE4	COMPLETED	Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
NCT00186017	PHASE4	COMPLETED	Short Term Rescue Study of Olanzapine
NCT00188942	PHASE4	COMPLETED	A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder
NCT00190749	PHASE4	COMPLETED	Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
NCT00190892	PHASE4	COMPLETED	Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania
NCT00191399	PHASE4	COMPLETED	Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response
NCT00191555	PHASE4	COMPLETED	Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
NCT00191828	PHASE4	COMPLETED	A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme
NCT00191997	PHASE4	COMPLETED	Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

922 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
RISPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
BREXPIPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
CYPROHEPTADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
ERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6
QUETIAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
ZIPRASIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1E, HTR2A, HTR2C, HTR6, HTR7
KETANSERIN	ChEMBL	Phase 4 (approved)	ADRA1A, DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR6, HTR7
YOHIMBINE	ChEMBL + PubChem	Phase 3 (approved)	ADRA1A, ADRA1D, DRD2, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR6
LATREPIRDINE	ChEMBL	Phase 3	ADRA1A, ADRA1D, DRD2, HRH1, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7
RITANSERIN	ChEMBL	Phase 2	ADRA1A, DRD2, HRH1, HTR1A, HTR1B, HTR1E, HTR2A, HTR2C, HTR6, HTR7
ASENAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1E, HTR2A, HTR2C, HTR6
METHYLERGONOVINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, DRD2, HRH1, HTR1A, HTR1E, HTR1F, HTR2A, HTR2C, HTR6
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR1E, HTR2A, HTR7
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
DOXEPIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
KETOTIFEN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1B, HTR2A, HTR2C, HTR6, HTR7
PROMAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
SALMETEROL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR7
SERTINDOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR2A, HTR2C, HTR6
TEGASEROD	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HTR1A, HTR1D, HTR2A, HTR2C, HTR6, HTR7
THIORIDAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
VILAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR6, HTR7
SEROTONIN	ChEMBL + PubChem	Phase 3 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
LYSERGIDE	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7
MEBUFOTENIN	ChEMBL	Phase 2	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
METERGOLINE	ChEMBL	Phase 2	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
NIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1B, HTR2C, HTR6, HTR7
PENFLURIDOL	ChEMBL	Phase 2	ADRA1D, DRD2, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR6, HTR7
SPIRAMIDE	ChEMBL	Phase 2	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR1D, HTR2A, HTR6, HTR7
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, DRD2, HRH1, HTR1B, HTR1D, HTR2A, HTR2C, HTR7
Pyrazinamide	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
RIZATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C
SORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, HTR1A, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7
SUMATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR7
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6
BUSPIRONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HTR1A, HTR2A, HTR2C, HTR6, HTR7
CINACALCET	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR6, HTR7
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR7
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6
LOXAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
MAPROTILINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6
METHYSERGIDE	ChEMBL	Phase 4 (approved)	ADRA1A, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6
PERGOLIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6